<DOC>
	<DOCNO>NCT01204294</DOCNO>
	<brief_summary>The objective current study investigate safety efficacy linagliptin ( 5mg / daily ) give 52 week add-on therapy patient type 2 diabetes mellitus insufficient glycaemic control despite diet , exercise , treatment one approve antidiabetic drug .</brief_summary>
	<brief_title>Comprehensive Add Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis type 2 diabetes mellitus 2 . Male female patient diet exercise regimen treat one antidiabetic drug Exclusion criterion : 1 . Myocardial infarction , stroke , transient ischemic attack , pulmonary embolism 2 . Impaired hepatic function 3 . Glitazone , glinide , sulfonylurea group : renal failure renal impairment define estimate glomerular filtration rate &lt; 30 ml/min ( severe renal impairment ) Visit 1 , Biguanide group : renal failure renal impairment define estimate glomerular filtration rate &lt; 60 ml/min ( moderate renal impairment ) Visit 1 4 . Treatment antiobesity drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>